1. Home
  2. Clinical Evidence

Predictive Technologies

Control-IQ Technology

Jun 2022 - Evaluation of long-term glycemic outcomes by ethnicity in adults with type 1 diabetes using Control-IQ technology
VIEW STUDY OVERVIEW
Jun 2022 - Psychosocial Benefits of using Control-IQ technology: Long-term Outcomes from a Multi-ethnic Adult Cohort with Type 1 Diabetes
VIEW STUDY OVERVIEW
Jun 2022 - Long-term Glycemic Control in Adult Participants Using Control-IQ Technology: Real-World Evidence
VIEW STUDY OVERVIEW
Apr 2022 - Time of Initiation of Advanced Hybrid Closed-Loop Therapy and Related Glycemic Outcomes in People with Type 1 Diabetes Transitioning from Multiple Daily Injections
VIEW STUDY OVERVIEW
Apr 2022 - Long-Term Improvements in Patient-Reported Outcomes Irrespective of Baseline Glycemic Control and Previous Insulin Delivery Method with the t:slim X2 Insulin Pump with Control-IQ Technology
VIEW STUDY OVERVIEW
Apr 2022 - Glycemic Outcomes by Age and Previous Insulin Delivery Method in Control-IQ Technology Users: 9 Months of CLIO Study Data
VIEW STUDY OVERVIEW
Oct 2021 - Candidate Selection for Hybrid Closed Loop Systems
Go to Publication
Sep 2021 - Patient Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed Loop Trial
Go to Publication
July 2021 - Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes
Go to Publication
Jun 2021 - Initiating hybrid closed loop: A program evaluation of an educator-led Control-IQ follow-up at a large pediatric clinic
Go to Publication
Jun 2021 - “I Feel Human, I Feel Normal”: A Qualitative Study of Experiences with Control-IQ Technology in Early Adopters
Go to Publication
Jun 2021 - Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Go to Publication
May 2021 - Efficacy of Closed-Loop Insulin Therapy in Adults Prone to Hypoglycemia – The International Diabetes Closed-Loop Trial Protocol 2.
Go to Publication
May 2021 - Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents
Go to Publication
Apr 2021 - Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Go to Publication
Apr 2021 - Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers
Go to Publication
Apr 2021 - Significant improvement in sensor time in range and hyperglycemia outcomes in 6 to 13-year-old children with type 1 diabetes using Control-IQ technology in the real-world
Go to Publication
Mar 2021 - One Year Real-World Use of Control-IQ Advanced Hybrid Closed-Loop Technology
Go to Publication
Feb 2021 - A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes
Go to Publication
Jan 2021 - Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Go to Publication
Jan 2021 - Pediatric Diabetes "Initiating Hybrid Closed Loop: A Program Evaluation of an Educator-Led Control-IQ Follow-up at a Large Pediatric Clinic"
Go to Publication
Dec 2020 - Automated Insulin Delivery: Easy Enough to Use in Primary Care?
Go to Publication
Dec 2020 - Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Go to Publication
Dec 2020 - Automated Insulin Delivery: Easy Enough to Use in Primary Care?
Go to Publication
Nov 2020 - Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-loop Control System
Go to Publication
Nov 2020 - Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop (iDCL) Trial
Go to Publication
Nov 2020 - Significant Reduction in Time Below Range (Hypoglycemia) in People with Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System
VIEW STUDY OVERVIEW
Sep 2020 - Psychosocial Impact of Control-IQ Technology in Pediatric Users with Type 1 Diabetes: Real-World Insights from the United States
View Study Overview
Sep 2020 - Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Go to Publication
Sep 2020 - Glycaemic control improves over 4 month use of closed loop insulin delivery in school-age children with type 1 diabetes
Go to Publication
Aug 2020 - Significant Improvements in Time Above Range Using Control-IQ Technology: Real-World Insights
View Study Overview
Aug 2020 - A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Go to Publication
Jun 2020 - Glycemic Outcomes for People with Type 1 and Type 2 Diabetes Using Control-IQ Technology: Real-World Data From Early Adopters
View Study Overview
Jun 2020 - Control-IQ Technology in the Real World: The First 30 days
View Study Overview
Jun 2020 - A Clinical Review of the t:slim X2 Insulin Pump
Go to Publication
May 2020 - Glycemic Outcomes of Use of Closed-Loop Control vs PLGS on Type 1 Diabetes: A Randomized Controlled Trial
Go to Publication
Feb 2020 - The Usability of a Hybrid Closed-Loop Insulin Delivery System: Simulated Use Studies of The Tandem t:slim X2 Insulin Pump with Control-IQ Technology
View Study Overview
Oct 2019 - Six-Month Randomized, Multi-Center Trial of Closed-Loop Control in Type 1 Diabetes
Go to Publication
Jun 2019 - Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Go to Publication
May 2019 - Closed-Loop Control in Adolescents and Children During Winter Sports: Use of the Tandem Control-IQ Artificial Pancreas System
Go to Publication
Apr 2019 - Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial
Go to Publication
Mar 2019 - Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Go to Publication
Feb 2019 - The International Diabetes Closed-Loop (IDCL) Study: Planned Pivotal Trials of Closed-Loop Control on an Embedded System and a Mobile System
Go to Publication
Dec 2018 - First Look at Control-IQ: A New Generation Automated Insulin Delivery System
Go to Publication
Aug 2017 - Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study
Go to Publication
Nov 2015 - Measures of Risk and Glucose Variability in Adults Versus Youths
Go to Publication
May 2014 - Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
Go to Publication
Jan 2014 - Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators
Go to Publication

Basal-IQ Technology

Nov 2020 - Differences in Perceived Quality of Sleep and Satisfaction with Insulin Delivery Device in People With Diabetes
VIEW STUDY OVERVIEW
Aug 2020 - Basal-IQ Technology in the Real-World: Satisfaction and Reduction of Diabetes Burden in Individuals With Type 1 Diabetes
Go to Publication
Jul 2020 - Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort Pre- and Post-Tandem Basal-IQ Technology Remote Software Update
Go to Publication
Jun 2020 - A Clinical Review of the t:slim X2 Insulin Pump
Go to Publication
May 2020 - Patient Perspectives on Satisfaction and Trust Related to Insulin Delivery Devices
View Study Overview
May 2020 - Psychosocial Benefits of Using Basal-IQ Predictive Low Glucose Suspend Technology in a Real-World Setting: Results From Pediatric Patients With Type 1 Diabetes
Go to Publication
May 2020 - Glycemic Outcomes of Use of Closed-Loop Control vs PLGS on Type 1 Diabetes: A Randomized Controlled Trial
Go to Publication
Nov 2019 - Real-World Patient Experience from 5,024 Patients Using the t:slim X2 Insulin Pump With Basal-IQ Technology
View Study Overview
Oct 2019 - Improvement in Hypoglycemia Outcomes in a Pediatric Population Using Predictive Low-Glucose Suspend
View Study Overview
Aug 2019 - Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort
Go to Publication
Jun 2019 - Real-World Psychosocial Outcomes and Ease of Use Predict Trust in Automated Insulin Delivery Systems
View Study Overview
Jun 2019 - Early Real-World Hypoglycemia Outcomes With Use of the Tandem Basal-IQ Technology System
View Study Overview
Oct 2018 - Predictive Low Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study
Go to Publication

Product Documentation

Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.

View Documentation

Product Training

Use our education tutorials to train your patients or CDEs on our easy-to-use products.

View Resources

Prescribing

Prescribing is easy with our customized referral process and insurance benefits check.

Learn More

Responsible Use of Control-IQ Technology

Even with advanced systems such as the t:slim X2 insulin pump with Control-IQ technology, patients are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that patients accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Since there are situations and emergencies that the system may not be capable of identifying or addressing, patients should always pay attention to their symptoms and treat accordingly.

Responsible Use of Basal-IQ Technology

Systems like the t:slim X2 insulin pump with Basal-IQ technology are not substitutes for the active management of diabetes. There are common scenarios in which automated systems cannot prevent a hypoglycemic event. The Basal-IQ feature relies on current CGM sensor readings to function and will not be able to predict glucose levels and suspend insulin delivery if a patient’s CGM is not functioning properly or his/her pump is unable to receive the CGM signal. It’s recommended your patient always uses the components of the pump system (pump, cartridges, CGM, and infusion sets) according to the applicable instructions for use and checks them regularly to make sure they are functioning as expected. Patients should always pay attention to their symptoms, actively monitor and manage glucose levels, and treat according to your recommendations.

Important Safety Information

RX ONLY. The t:slim X2 insulin pump, Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, Basal-IQ technology, and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.

t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals six years of age and greater. Basal-IQ technology:Basal-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically suspend delivery of insulin based on iCGM readings and predicted glucose values. The bolus calculator is indicated for the management of diabetes by people with diabetes by calculating an insulin dose or carbohydrate intake based on user entered data. Basal-IQ technology is intended for the management of diabetes mellitus in persons six years of age and greater. Control-IQ technology:Control-IQ technology is intended for use with a compatible iCGM (sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.

WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

 
Control-IQ technology and Basal-IQ technology are not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump, Basal-IQ technology, and Control-IQ technology must: be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. visit www.tandemdiabetes.com/safetyinfo for additional important safety information.